1-20 of 132 results for askedby:"Lord Saatchi"
Librarians' tools
- Search time
- 0.225 seconds
- Solr query time
- 0.002 seconds
- Search query
- askedby:"Lord Saatchi"
- We searched for
- tablingMember_ses:303387 OR askingMember_ses:303387
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask Her Majesty's Government what assessment they have made of (1) the proposals of the Lead Not Leave campaign, in particular to move from debating terms for leaving the EU to terms for remaining in the EU, and (2) the potential benefits of the UK remaining in the EU...
To ask Her Majesty's Government what assessment they have made of (1) the proposals of the Lead Not Leave campaign, in particular to move from debating terms for leaving the EU to terms for remaining in the EU, and (2) the potential benefits of the UK remaining in the EU...
The Government’s policy is to work with Parliament to deliver a deal that ensures we leave the European Union, as planned, on March 29th.
Revoking Article 50 would not only betray the vote of the British people in the 2016 referendum, but it would betray the mandates on which the majority of MP’s were elected into Parliament.
The British people gave a clear instruction to leave and we are delivering on that instruction.
My Lords, would my noble friend allow me to share the latest figures with your Lordships’ House? The number of lawsuits filed against the NHS last year was double the level of four years ago. Last year the payout of claims against the NHS was £1.2 billion. The current Treasury provision for likely payouts in the future for litigation against the NHS is now over £19 billion. Against that backdrop, is there not a danger that the growing fear of medical litigation leads to a growing bias against medical innovation? Will my noble friend consider the warnings of judges about the tendency of current law to inhibit medical progress? For example—
My Lords, would my noble friend allow me to share the latest figures with your Lordships’ House? The number of lawsuits filed against the NHS last year was double the level of four years ago. Last year the payout of claims against the NHS was £1.2 billion. The current Treasury provision for likely payouts in the future for litigation against the NHS is now over £19 billion. Against that backdrop, is there not a danger that the growing fear of medical litigation leads to a growing bias against medical innovation? Will my noble friend consider the warnings of judges about the tendency of current law to inhibit medical progress? For example—
My Lords, naturally I share my noble friend’s concern about the level of litigation in the NHS. Having said that, I have seen no evidence that a particularly large or indeed significant element of that bill relates to medical innovation. We need to reflect that all treatments in routine use in the NHS today began as innovative treatments. We continue to support the introduction of new and innovative treatments in the NHS. I think that, if anything, doctors have more concerns about being reported to the General Medical Council than they do about being sued.
To ask Her Majesty’s Government what assessment they have made of the impact of medical litigation on medical innovation.
To ask Her Majesty’s Government what assessment they have made of the impact of medical litigation on medical innovation.
My Lords, it is the Department of Health’s view that no assessment is required as no changes are needed to the law or medical guidance in this area. The current system allows for doctors to initiate novel treatments provided that they are evidence-based, in the best interests of the patient, and with patient consent. While the law does not seek to block innovation, it does require new forms of treatment to be rigorously tested before being introduced.
To ask Her Majesty’s Government what assessment they have made of the impact of the current law on medical negligence on scientific discovery in cancer. [HL1026]
To ask Her Majesty’s Government what assessment they have made of the impact of the current law on medical negligence on scientific discovery in cancer. [HL1026]
The Government has not made any assessment of the impact of the current law on medical negligence on scientific discovery in cancer.
To ask Her Majesty’s Government what advice they offer to doctors about the risks of prosecution for medical negligence if they deviate from standard procedure.[HL1028]
To ask Her Majesty’s Government what advice they offer to doctors about the risks of prosecution for medical negligence if they deviate from standard procedure.[HL1028]
The Government is not in a position to give legal advice to doctors. The law allows doctors to initiate novel treatments which may require them to deviate from standard procedure, as long as they are done in the best interests of the patient and with patient consent.
Negligence is not set out in statute but is developed through the Courts i.e. it falls under Tort law. The Courts look at a range of facts presented in each case, including acts and omissions to act, and the defendant will need to show they met their duty of care in relation to the individual that has been harmed so as not to have been negligent in breaching the duty.
To ask Her Majesty’s Government what progress Sir David Nicholson has made in encouraging a culture change towards innovation within the National Health Service.[HL1025]
To ask Her Majesty’s Government what progress Sir David Nicholson has made in encouraging a culture change towards innovation within the National Health Service.[HL1025]
In December 2011, the National Health Service Chief Executive Sir David Nicholson published a report entitled, Innovation health and wealth, accelerating adoption and diffusion in the NHS. This articulated the importance of innovation in NHS England's ambition to ramp up the pace and scale of change, and deliver better outcomes for patients across all five domains of the NHS Outcomes Framework. Since publication, NHS England has progressed a number of key programmes including the National Institute for Health and Care Excellence implementation collaborative, Academic Health Science Networks and
the Innovation scorecard. These and other initiatives are helping to embed a coordinated approach and greater awareness of the importance of innovative thinking and practice throughout the health care system.
In addition, a new dedicated Innovation Team has been established within NHS England's Medical Directorate. The team works across the NHS, social care, academia and industry on a range of initiatives which facilitate the generation, identification, adoption and diffusion of innovative ideas, products and technologies.
To ask Her Majesty’s Government what assessment they have made of the future viability of randomised controlled trials.[HL1027]
To ask Her Majesty’s Government what assessment they have made of the future viability of randomised controlled trials.[HL1027]
The Department has made no specific assessment of this issue.
To ask Her Majesty’s Government in what proportion of deaths recorded as caused by cancer is the actual cause of death the treatment of cancer.
To ask Her Majesty’s Government in what proportion of deaths recorded as caused by cancer is the actual cause of death the treatment of cancer.
The Office for National Statistics publishes national cancer mortality data annually. Data are collected where cancer has been recorded as the cause of death, but not on treatment for cancer as the cause of death. I therefore regret that I am unable to provide this information.
My Lords, I thank my noble friend for that reply. The point of this Question is that there is no Answer it. Since I tabled the Question, I have received an estimate from within the medical profession that last year 15,000 people in Britain were killed by cancer treatment rather than by cancer. We do not know whether 1% or 100% of patients die as result of the treatment; what we do know is that cancer drugs do such damage to the immune system that the patient is helpless to resist fatal infections such as MRSA, E. coli or septicaemia. Does my noble friend agree, as I think he has, that the official statistics for the UK cannot distinguish between cancer death and treatment for cancer death? Is this not because the ONS, under WHO guidelines, records only the single underlying cause of death? In other words, it does not record the sequence of causation, sometimes known as the sequence of conditions, that led to the death. This is supposed to be the era of big data. Will my noble friend review the limitations of cancer mortality statistics in order to assist scientists and doctors to have the information to move forward innovation towards a cure for cancer?
My Lords, I thank my noble friend for that reply. The point of this Question is that there is no Answer it. Since I tabled the Question, I have received an estimate from within the medical profession that last year 15,000 people in Britain were killed by cancer treatment rather than by cancer. We do not know whether 1% or 100% of patients die as result of the treatment; what we do know is that cancer drugs do such damage to the immune system that the patient is helpless to resist fatal infections such as MRSA, E. coli or septicaemia. Does my noble friend agree, as I think he has, that the official statistics for the UK cannot distinguish between cancer death and treatment for cancer death? Is this not because the ONS, under WHO guidelines, records only the single underlying cause of death? In other words, it does not record the sequence of causation, sometimes known as the sequence of conditions, that led to the death. This is supposed to be the era of big data. Will my noble friend review the limitations of cancer mortality statistics in order to assist scientists and doctors to have the information to move forward innovation towards a cure for cancer?
My Lords, I agree that it is important to have more information on the effect of cancer treatments on mortality. New data collections which will provide more detail in this area are under way. The systemic anti-cancer therapy dataset will enable better information to be collected about deaths after the delivery of chemotherapy, and the cancer outcomes and services data set will provide information in respect of death after surgical treatment. However, it is important to make one point here: it can be hard to identify the precise cause or sequence of progression of factors resulting in death, particularly for those with end-stage cancer or who are particularly frail and are experiencing physical deterioration. I do not think that it can ever be a precise science.
To ask Her Majesty's Government what is the United Kingdom market share of the top five companies in (a) retail banking, (b) corporate banking, (c) mortgages, (d) insurance and re-insurance, (e) Government bond issuance, (f) foreign exchange, and (g) credit swaps and derivatives.
To ask Her Majesty's Government what is the United Kingdom market share of the top five companies in (a) retail banking, (b) corporate banking, (c) mortgages, (d) insurance and re-insurance, (e) Government bond issuance, (f) foreign exchange, and (g) credit swaps and derivatives.